Ubiquitin/Cancer:Molecular Targets/Mechanisms to Clinic

泛素/癌症：临床分子靶点/机制

• 批准号: 7058936
• 负责人: CLAUDIO A.P. JOAZEIRO
• 金额: $ 0.5万
• 依托单位: AMERICAN ASSOCIATION FOR CANCER RESEARCH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-10 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7058936
• 关键词: meeting /conference /symposium; molecular oncology; proteasome; travel; ubiquitin

DESCRIPTION (provided by applicant): The aim of this proposal is to organize a conference titled "Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic" scheduled for January 18-22, 2006, at Disney's Contemporary Resort in Lake Buena Vista, Florida. This conference is unique among other meetings in the protein ubiquitylation field for its strong clinical/translational component (1/3 of all talks), including the opportunity to review the recent successes with proteasome.inhibitors in treating cancer in the clinic, as well as the pre-clinical studies validating ubiquitin ligase inhibitors for cancer therapy. Thus, there will be little overlap with other planned meetings on the UPS because of its more focused program, with respect both to the cell biology processes and to the disease that will be covered. Specifically, the meeting objectives are: 1) to provide an overview of the field of protein ubiquitylation, including review and discussion of the UPS-mediated regulation of various cellular processes that are relevant for cancer; 2) to foster discussions on the role of the UPS in malignancy and the opportunities for therapeutic intervention (drug targets); 3) to evaluate the successes and limitations of existing as well as proposed therapeutic approaches to interfere with the UPS; 4) to provide a forum for interaction among cancer scientists and experts in the field of protein ubiquitylation; 5) to contribute to the education of young scientists and others interested in the fields of cancer and the UPS. The field of protein ubiquitylation and degradation has experienced explosive growth in the past decade. The UPS regulates an enormous range of biological processes, including cell cycle, apoptosis, protein trafficking, signaling, DMA replication and repair, and angiogenesis. Consistently, defects in the UPS have already been directly implicated with many diseases. Deregulated protein ubiquitylation represents a major contributing factor for cancer development. Well known examples are the deregulation of the ubiquitin ligases BRCA1, Mdm2, VHL and Skp2 in various cancers. We expect that this meeting will foster extensive discussion on therapeutic opportunities, on therapeutic approaches and on the role of the UPS in malignancy. Emphasis will be given to the challenges involved in target identification and validation, and in drug development.

描述（由申请人提供）：该提案的目的是组织一次名为“泛素和癌症：从分子目标和机制到计划于2006年1月18日至22日在迪斯尼在佛罗里达州布埃纳维斯塔湖的当代度假胜地的诊所”的会议。 这次会议在蛋白质泛素化领域的其他会议上是独一无二的，其强大的临床/翻译成分（所有谈判的1/3），包括有机会回顾临床治疗癌症的最新成功，以及对临床前研究的抑制作用，以及验证了对泛素络合蛋白有关癌症治疗的差异前研究。因此，由于其更为专注的计划，与细胞生物学过程和将要涵盖的疾病有关，因此UPS上的其他计划会议几乎没有重叠。 具体而言，会议目标是：1）提供蛋白质泛素化领域的概述，包括对UPS介导的与癌症相关的各种细胞过程的审查和讨论； 2）促进有关UPS在恶性肿瘤和治疗干预机会的作用的讨论（药物靶标）； 3）评估现有的成功和局限性以及拟议的治疗方法来干扰UPS； 4）为蛋白质泛素化领域的癌症科学家和专家之间的相互作用提供论坛； 5）为年轻科学家以及对癌症和UPS领域感兴趣的其他人的教育做出贡献。 在过去的十年中，蛋白质泛素化和降解的领域经历了爆炸性的增长。 UPS调节大量生物学过程，包括细胞周期，凋亡，蛋白质运输，信号传导，DMA复制和修复以及血管生成。一致地，UPS中的缺陷已经与许多疾病直接牵连。 放松管制的蛋白质泛素化代表了癌症发展的主要因素。众所周知的例子是各种癌症中泛素连接酶BRCA1，MDM2，VHL和SKP2的放松管制。 我们预计，这次会议将促进有关治疗机会，治疗方法和UPS在恶性肿瘤中的作用的广泛讨论。 将重点放在目标识别和验证以及药物开发中所涉及的挑战。